文献速递卫生政策与健康促进

2002-15年全球卫生创新融资工具:系统分析

Innovative financing instruments for global health 2002-15: a systematic analysis.
PubMed 文献 · Lancet Glob Health · 2017-01-01

资金主要经全球疫苗免疫联盟和全球基金,用于疫苗、艾滋病、疟疾、结核及妇幼卫生,未见明确针对非传染性疾病的资金。

要点

  • 资金主要经全球疫苗免疫联盟和全球基金分配。

研究设计与样本

  • 系统分析,识别2002至2015年间十种创新融资工具并估算其动员资金量。

主要发现

  • 资金主要经全球疫苗免疫联盟和全球基金分配,用于新疫苗和未充分利用疫苗、艾滋病、疟疾、结核及妇幼卫生项目。
  • 未见明确针对非传染性疾病的资金。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Development assistance for health (DAH), the value of which peaked in 2013 and fell in 2015, is unlikely to rise substantially in the near future, increasing reliance on domestic and innovative financing sources to sustain health programmes in low-income and middle-income countries. We examined innovative financing instruments (IFIs)-financing schemes that generate and mobilise funds-to estimate the quantum of financing mobilised from 2002 to 2015. We identified ten IFIs, which mobilised US$8·9 billion (2·3% of overall DAH) in 2002-15. The funds generated by IFIs were channelled mostly through GAVI and the Global Fund, and used for programmes for new and underused vaccines, HIV/AIDS, malaria, tuberculosis, and maternal and child health. Vaccination programmes received the largest amount of funding ($2·6 billion), followed by HIV/AIDS ($1080·7 million) and malaria ($1028·9 million), with no discernible funding targeted to non-communicable diseases.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Atun R, Silva S, Knaul FM, et al. Innovative financing instruments for global health 2002-15: a systematic analysis. Lancet Glob Health. 2017. PMID: 28619230. doi:10.1016/S2214-109X(17)30198-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。